Novel mutation in a family with WNT1-related osteoporosis

Eur J Med Genet. 2018 Jul;61(7):369-371. doi: 10.1016/j.ejmg.2018.01.017. Epub 2018 Feb 23.

Abstract

Osteogenesis imperfecta (OI) is an inherited disorder with osteoporosis and recurrent fractures. Children presenting with recurrent fractures and bowing of limbs have severe form of the disorder. Patients carrying homozygous WNT1 mutations have more frequent fractures while heterozygous carriers of the mutation in WNT1 gene are also found to have early onset osteoporosis. We identified a family with novel WNT1 mutation. The index case, a 6 month old child presented with fractures from early infancy. Next generation sequencing (NGS)done for the child didn't show any variations in other OI genes including COL1A1, COL1A2, SERPINH1, CRTAP, LEPRE1, PP1B, 1F1TM5 and BMP1 genes. Sanger sequencing showed 41bp deletion in splice region following exon 1 of WNT1 gene in homozygous state. The mutation was found to be likely pathogenic on bioinformatic analysis. To further characterize the significance of the mutation we studied his mother who is 30 year old with blue sclera and history of backache but no fractures. Her DXA scan of lumber spine showed osteoporosis and she was heterozygous for the mutation. The child's DXA scan showed T-score of -6.4 at lumbar spine level. Father also has history of backache and was carrier for the same deletion variant. The child was given 3 doses of zoledronate and did not have any further fractures. Thus, we conclude that this novel variant identified in the child with OI is likely cause for the disease and possibly zoledronate has a role in prevention of fractures in this case.

Keywords: Fractures; OI type XV; Osteogenesis imperfecta; Osteopenia; Zoledronate.

Publication types

  • Case Reports

MeSH terms

  • Bone Density Conservation Agents / therapeutic use
  • Diphosphonates / therapeutic use
  • Fractures, Bone / genetics*
  • Genetic Variation
  • Humans
  • Imidazoles / therapeutic use
  • Infant
  • Male
  • Mutation
  • Osteogenesis Imperfecta / drug therapy
  • Osteogenesis Imperfecta / genetics*
  • Wnt1 Protein / genetics*
  • Zoledronic Acid

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • WNT1 protein, human
  • Wnt1 Protein
  • Zoledronic Acid